Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
sarepta therapeutics股價上漲，公司發佈了好於預期的第三季度財務業績。此外，康泰爾菲茨傑拉德將股票評級從中立調升至超配，並將目標股價從152美元提高到167美元。
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
Sarepta Therapeutics公佈的第三季度財務業績好於預期後，該公司股價走高。此外，坎託·菲茨傑拉德將該股從中性上調至增持，並將其目標股價從152美元上調至167美元。
資訊熱榜
更新時間